About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune ...
MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
SAB BIO to Host Webinar Discussing Topline Results from Phase 1 Trial of SAB-142 for Type 1 Diabetes
SAB BIO will host a webinar on January 28, 2025, to discuss Phase 1 trial data for its T1D therapy, SAB-142. SAB BIO, a clinical-stage biopharmaceutical company, announced it will host a webinar on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results